Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. - Wikidata - awgldk - TriplyDB

Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.

Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.

http://www.wikidata.org/entity/Q37336299

about

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus Current understanding of conventional outflow dysfunction in glaucoma Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo Critical evaluation of latanoprostene bunod in the treatment of glaucoma Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study Pharmaceutical intervention for myopia control.Analyzing live cellularity in the human trabecular meshwork Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost.Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension Sphingolipids and ceramides of mouse aqueous humor: Comparative profiles from normotensive and hypertensive DBA/2J mice.[Effectiveness of selective laser trabeculoplasty in patients with insufficient control of intraocular pressure despite maximum tolerated medical therapy].A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 μg/mL to latanoprost 50 μg/mL (xalatan) in the treatment of primary open-angle glaucoma and ocular hypertension Prostaglandin-induced cystoid macular edema following routine cataract extraction.Regulation of retinal proteome by topical antiglaucomatous eye drops in an inherited glaucoma rat model Effects of prostaglandin analogues on aqueous humor outflow pathways.Targeted delivery of antiglaucoma drugs to the supraciliary space using microneedles.Thermal stability of bimatoprost, latanoprost, and travoprost under simulated daily use.Clinical options for the reduction of elevated intraocular pressure A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells.The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies.Glaucoma management: relative value and place in therapy of available drug treatments.Trans-conjunctival aqueous humor outflow in glaucomatous patients treated with prostaglandin analogues: an in vivo confocal microscopy study.Is There Any Role for the Choroid in Glaucoma?Expression profile of the matricellular protein osteopontin in primary open-angle glaucoma and the normal human eye.Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.Head-down posture induces PERG alterations in early glaucoma.Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases.Effects of Latanoprost and Bimatoprost on the Expression of Molecules Relevant to Ocular Inflow and Outflow Pathways Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy Formulation to target delivery to the ciliary body and choroid via the suprachoroidal space of the eye using microneedles Topical prostaglandin analogues and conjunctival inflammation in uveitic glaucoma Bilateral serous detachment associated with latanoprost/timolol fixed combination use: a report of one phakic case.Effect of topical latanoprost 0.005% on intraocular pressure and pupil diameter in normal and glaucomatous cats Comparative phospholipid profiles of control and glaucomatous human trabecular meshwork Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma.Imaging the effects of prostaglandin analogues on cultured trabecular meshwork cells by coherent anti-stokes Raman scattering

P2860

Q26830201-1FB87A11-D680-454A-9777-010B0BEAB4B7 Q26991731-880906A0-27A2-4A68-9B6E-8F8962F7FA27 Q27024271-4708DC92-925F-4DE7-A3E1-15772E17BCA8 Q28077208-92963923-61D1-4768-A2AB-6162161848D8 Q28548224-05C76075-9504-40D6-A696-185625AC35DA Q30472509-306B37BF-3648-469C-AAE6-713585F3023D Q30534775-F9C26AE5-3805-4C32-8955-67797C9091F8 Q33687798-5FC11705-9A29-4913-BCA3-69FDBDC7BEB3 Q33727601-D2F3EDC2-4DB0-4E7F-802D-A87541E3F981 Q33857744-459CED72-2E4B-4CD4-8871-D4E259779017 Q34043309-C534E855-8E00-47A6-87E9-290771A944A0 Q34177887-BB2C26B2-5B64-414E-B200-4EF6CEB6297F Q34255437-D05ADA66-DF92-4818-A39B-493009EBD2F2 Q34274254-59798F1F-C192-4D03-9A93-CB6095874F74 Q34284681-22EE700F-CFDF-4450-B4E9-7E13FA67AB3E Q34335584-E590DF71-492A-41F3-9440-E1241291E4ED Q34393424-E090A497-8325-49DC-BCFE-9E472DF59ABC Q34511234-393C7721-F62B-457D-925A-E730BE613417 Q34570414-A018E107-9769-4A4D-B65D-56CDB3FA6D5C Q34708267-929EC61F-499A-4624-AE62-0A8EFE8FF9A8 Q34708308-7C6028D5-BAB5-43AD-B144-769ACC40EBBA Q34730252-7E2B7D4E-EB99-437B-A0C1-60366EEC1A9C Q34731426-B066452C-0EF8-434B-8220-3F69FB1DCA3E Q35079342-8B8B4A17-1939-4005-BFEF-EB2AF0412ACB Q35175058-E012003B-1085-46B5-9B83-1F53EEB19BEE Q35220605-2D20EAF4-210E-4C6F-AB90-59F8B3AC8AC3 Q35221250-6E167378-64A0-4B98-95AE-D8FC02F65F0F Q35617544-090EEF7D-F404-4CDA-B328-6A4DFFCC6A49 Q35681331-9ABB7EA3-646F-4EED-8134-3FD52D3A1447 Q35812926-AC3810EC-A703-4C27-BE8D-6816480D0AEF Q35949978-4B0993D4-0B19-41FB-8ED9-CB49ACB43E3B Q35969296-2D11A9BA-B4E5-45C2-8BA4-94169B95F1BC Q36044733-31037C1E-E505-405E-B29C-09A91AA033BD Q36157157-EC1431D4-FD84-452D-887F-5E41405C11FA Q36192495-AE2F5716-2D83-4242-83F6-A303CC9644FD Q36495854-50D98D4B-52A8-40DC-9FF5-A97B2D57CE38 Q36586496-337E1898-4546-43BB-A966-FFDA15AC77B8 Q36807917-759EF998-6AA6-4A69-A763-5A9C77447886 Q36908446-0E07DDAB-EE7E-4035-836E-B5A9E708447E Q37145625-8FF3DB7B-5FF0-42E4-9A9D-CC6D885790A9

P2860

Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction.

http://www.wikidata.org/entity/Q37336299

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Update on the mechanism of act ...... ntraocular pressure reduction.

@en

Update on the mechanism of act ...... ntraocular pressure reduction.

@nl

type

label

Update on the mechanism of act ...... ntraocular pressure reduction.

@en

Update on the mechanism of act ...... ntraocular pressure reduction.

@nl

prefLabel

Update on the mechanism of act ...... ntraocular pressure reduction.

@en

Update on the mechanism of act ...... ntraocular pressure reduction.

@nl

P1433

Q37336299-FEA8F3BF-64C5-4E32-82F6-4811949B1DD5

P1476

Q37336299-62BEC4F3-3780-475F-9B61-DAAB7A680DE4

P2093

Q37336299-4A1569C9-E634-4BDB-83E9-C6C9946C4813

Q37336299-68508481-5B66-4B02-B64C-4E3FD698A6CD

Q37336299-966E1CE8-2691-48AE-A699-CB369A7C0FC0

P2860

Q37336299-062C783C-631D-42A1-AC9B-BED6D115BC3E

Q37336299-11927A64-8BB9-497C-9000-2CF1C3BED6B2

Q37336299-17285145-25BF-48EE-AD0A-0B4CAF0D8AB6

Q37336299-183CD81D-1CA8-4E63-AF00-F55844BDF706

Q37336299-188AA5BF-27B6-4D91-A976-14799D490165

Q37336299-28704007-1BE4-42AC-BDB2-C5CF83C276FB

Q37336299-2DE1BC19-2628-4CBA-A307-A759059EDFDB

Q37336299-34673654-1652-482E-AF22-F3FEC8038AAA

Q37336299-37341585-A33A-43AE-832E-CBDC59338981

Q37336299-397B344C-7BC0-4660-97AC-EDE1023F39AF

P304

Q37336299-A59DFEF0-0153-4D61-A436-C00F94AFB720

P31

Q37336299-9AF117F7-1A5D-4FF2-AB40-C86F07A7212D

P356

Q37336299-F41FF517-021F-452C-8A0F-9230F46AE3FC

P478

Q37336299-CFECAC3E-0991-488D-BDE6-EC2D93820859

P577

Q37336299-0C231624-CE77-43D5-9328-4F25A6A85982

P5875

Q37336299-83D3DD0B-9E4C-489F-94A8-53A866288186

P698

Q37336299-6E3A9958-16A4-4F8D-BE2A-EB544C42B73C

P932

Q37336299-14C12BD7-3A8F-454D-9DA4-44373B8FE9A9

P356

J.SURVOPHTHAL.2008.08.010

P1433

Survey of Ophthalmology

P1476

Update on the mechanism of act ...... ntraocular pressure reduction.

@en

P2093

B'Ann T Gabelt

http://www.w3.org/2001/XMLSchema#string

Carol B Toris

http://www.w3.org/2001/XMLSchema#string

Paul L Kaufman

http://www.w3.org/2001/XMLSchema#string

P2860

Tissue inhibitors of metalloproteinases: evolution, structure and function

Enhancement of scleral macromolecular permeability with prostaglandins

Effect of 15-keto latanoprost on intraocular pressure and aqueous humor dynamics in monkey eyes.

Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes.

Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics.

Effect of 8-iso prostaglandin E2 on aqueous humor dynamics in monkeys.

Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells.

Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.

Effects of travoprost on aqueous humor dynamics in monkeys.

Effects of a prostaglandin DP receptor agonist, AL-6598, on aqueous humor dynamics in a nonhuman primate model of glaucoma.

P304

S107-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SURVOPHTHAL.2008.08.010

http://www.w3.org/2001/XMLSchema#string

P478

53 Suppl1

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51435091

http://www.w3.org/2001/XMLSchema#string

P698

19038618

http://www.w3.org/2001/XMLSchema#string

P932

2727743

http://www.w3.org/2001/XMLSchema#string